You just read:

Kangpu Biopharmaceuticals Successfully Completed Phase I Study of Novel CRL4-CRBN Modulator KPG-818 in the U.S.

News provided by

Kangpu Biopharmaceuticals

Oct 11, 2019, 01:00 ET